The Quantellect read.As of Nov 19, 2026, 12 active firms cover Globus Medical: 9 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $80.00 to $123.00, a moderate spread. The average target of $98.25 sits 39% above the current $70.53. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.19 next quarter toward $5.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy975%
Neutral325%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$98.25
+39.3% upside
Average target across 12 active firms as of Nov 19, 2026 vs $70.53 current
Highest Target$123.00
Average Target$98.25
Lowest Target$80.00
Detailed analyst forecasts for GMED
Showing 1–13 of 13 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 9 of 12 active firms rate GMED a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GMED EPS & revenue forecast
EPS · NEXT QUARTER
$1.19
Range $1.09 – $1.28 · 10 analysts · +6% YoY
Next period, 10 analysts expect Globus Medical to earn $1.19 a share (range $1.09 – $1.28), versus $1.12 a year earlier. Full-year consensus is $4.98, growing to $5.34 the year after.
REVENUE · NEXT QUARTER
$768.5M
Range $725.4M – $795.2M · 10 analysts · +1% YoY
Revenue is expected to reach $768.5M (range $725.4M – $795.2M), +1.1% year-over-year. Full-year consensus is $3.1B, rising to $3.3B next year.
Top analysts covering Globus Medical
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GMED.
#1
Ryan Zimmerman
BTIG · Rank #212
Neutral
No targeton GMED
Overall win rate
37%
+ Follow
#2
CC
Caitlin Cronin
Canaccord Genuity · Rank #260
Buy
$115.00+63.1% to target
Overall win rate
39%
+ Follow
#3
William Plovanic
Canaccord Genuity · Rank #370
Buy
$90.00+27.6% to target
Overall win rate
38%
+ Follow
#4
JW
Jason Wittes
Roth MKM · Rank #382
Buy
$105.00+48.9% to target
Overall win rate
40%
+ Follow
#5
David Saxon
Needham · Rank #426
Buy
$117.00+65.9% to target
Overall win rate
32%
+ Follow
GMED stock forecast FAQ
What is GMED's average 12-month price target?+
The 12 active firms with a live target average $98.25 for Globus Medical over the next 12 months, ranging from a $123.00 high to a $80.00 low, as of Nov 19, 2026.
Is GMED stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GMED?+
The Street-high target is $123.00 (Barclays), and the Street-low is $80.00 (Stifel). The average of all 12 active-firm targets is $98.25.
How many active Wall Street firms cover GMED?+
12 active firms have a recognized rating on Globus Medical as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GMED?+
Among analysts who currently cover GMED, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Neutral.
What is Globus Medical's projected EPS for next quarter?+
The consensus estimate is $1.19 per share (range $1.09 – $1.28) across 10 analysts. Full-year EPS is projected at $4.98, rising to $5.34 the following year.
How much revenue is Globus Medical expected to report next quarter?+
Consensus revenue is $768.5M (range $725.4M – $795.2M). Full-year revenue is projected at $3.1B, growing to $3.3B next year.
Have analysts been upgrading or downgrading GMED lately?+
As of Nov 19, 2026, 9 of 12 active firms rate GMED a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GMED calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.